Description
About Cartalax
Cartalax is a short synthetic tripeptide composed of the three-amino-acid sequence Ala-Glu-Asp, commonly abbreviated as AED.
AED has been investigated in laboratory research involving mesenchymal stem cells, chondrocytes and cellular-ageing models. Mesenchymal stem cells can develop into several specialised cell types, including cartilage-forming chondrocytes, making their differentiation an important area of cartilage and tissue-engineering research.
Published experiments have examined whether AED influences chondrogenic differentiation — the process through which stem cells develop towards cartilage-forming cells — and the expression of genes and proteins associated with cartilage extracellular matrix.
Research has also examined AED in models of cellular ageing, including age-related changes in mesenchymal stem cells and chondrocytes.
Together, these research areas make Cartalax relevant to laboratory studies of cartilage-cell biology, chondrogenic differentiation, extracellular-matrix regulation and cellular ageing.
Pronoia supplies Cartalax in a higher-total-content 20mg lyophilised research format with batch traceability and supporting documentation available for the supplied material.
Product Specification
Product: Cartalax
Strength: 20mg
Peptide class: Synthetic tripeptide
Sequence: H-Ala-Glu-Asp-OH
Sequence notation: AED
Peptide length: 3 amino acids
Research focus: Chondrogenic differentiation, cartilage-matrix markers and cellular ageing
Form: Lyophilised solid
Pronoia minimum purity standard: ≥99%
Batch traceability: Maintained
SKU: PB-CART-20
Testing & Batch Documentation
Pronoia maintains a structured quality, testing and traceability process for Cartalax, with supporting documentation retained for the supplied research material.
- Batch-tested research material
- Pronoia minimum accepted purity standard of ≥98%
- Full batch traceability
- Batch-separated and labelled inventory
- Physical inventory routinely reconciled with digital stock records
- Temperature-controlled cold storage
- Certificate of Analysis (COA) and Safety Data Sheet (SDS) documentation available
The applicable Certificate of Analysis should be treated as the authoritative reference for the identity, purity and analytical results reported for an individual batch.
Research Context
Published experimental research has examined the Ala-Glu-Asp (AED) tripeptide in human mesenchymal stem cells and chondrocytes, with particular interest in cartilage-forming differentiation, extracellular-matrix-associated markers and cellular ageing.
One laboratory study investigated AED in human mesenchymal stem cells undergoing replicative ageing. Researchers examined gene expression and protein production associated with chondrogenic differentiation — the process through which stem cells develop towards cartilage-forming chondrocytes.
Under the experimental conditions used, AED was reported to increase gene expression and protein production of:
- SOX9, a transcription factor with a central role in cartilage-forming cell differentiation
- Aggrecan, a major proteoglycan component of cartilage extracellular matrix
- Type II collagen, an important structural protein within cartilage
- Cartilage oligomeric matrix protein (COMP), an extracellular-matrix protein associated with cartilage structure
These findings make AED relevant to experimental studies examining the molecular signals associated with chondrogenic differentiation and cartilage extracellular-matrix biology.
Separate research has examined AED in ageing chondrocytes — the specialised cells responsible for producing and maintaining cartilage matrix.
In cellular-ageing models, researchers have investigated AED in relation to senescence-associated signalling and regulatory markers, including proteins involved in cell-cycle control, inflammatory signalling and cellular stress responses.
Earlier research using ageing human mesenchymal stem-cell cultures has also investigated AED alongside other short peptides in relation to gene-expression pathways involving IGF1, FOXO1, TERT, TNKS2 and NFκB.
Together, these studies place AED within an emerging area of short-peptide research examining cartilage-cell biology, stem-cell differentiation, gene regulation and cellular ageing.
The evidence base remains predominantly preclinical and is concentrated in laboratory cell models. Findings from these experimental systems do not establish equivalent biological effects, clinical efficacy or safety in humans.
Storage & Handling
Cartalax is supplied in lyophilised form and should be stored according to the conditions specified by Pronoia and the applicable batch documentation.
Pronoia stock is maintained in temperature-controlled cold storage and organised by identifiable batch prior to dispatch.
The material should be protected from unnecessary exposure to heat, moisture and light and handled using appropriate laboratory procedures.
Where batch-specific storage or handling information is supplied, that information should take precedence.
UK Delivery
Cartalax is dispatched from Pronoia’s UK stock using tracked delivery.
Current availability and dispatch information are shown directly on the product page, with tracking supplied following dispatch.
Orders are prepared through Pronoia’s established research-product fulfilment process, with applicable delivery conditions remaining subject to Pronoia’s current delivery terms.
Research Use
Cartalax supplied by Pronoia Bio is intended for laboratory research and experimental use only.
It is not supplied for human or veterinary use and should not be treated as a medicine or consumer healthcare product.
Pronoia does not provide dosage, treatment or administration guidance for this research material.
